Novel and de novo mutations in pediatric refractory epilepsy

Jing Liu, Lili Tong, Shuangshuang Song, Yue Niu, Jun Li, Xiu Zhen Wu, Jie Zhang, Clement C. Zai, Fang Luo, Jian Wu, Haiyin Li, Albert H.c. Wong, Ruopeng Sun, Fang Liu, Baomin LiMolecular 2018 · DOI

Abstract

Pediatric refractory epilepsy presents a significant clinical challenge due to its vast genetic heterogeneity. This study investigated a cohort of 172 children (ages 0-14) with drug-resistant seizures using targeted next-generation sequencing (NGS) of 153 epilepsy-related genes. We identified pathogenic or likely pathogenic (P/LP) variants in 23.3% of patients. Notably, 74.4% of these mutations were de novo and 60.5% were novel. A significantly higher diagnostic yield was observed in patients with seizure onset before 12 months of age. Ion channel genes, particularly SCN1A, were the most frequent contributors to the genetic landscape. These findings emphasize the utility of early genetic screening in guiding precision treatment and genetic counseling.

Introduction

Pediatric refractory epilepsy—seizures that fail to respond to at least two appropriately chosen anti-epileptic drugs—is often rooted in complex genetic architectures. For many families, the lack of a clear diagnosis leads to a "diagnostic odyssey" and trial-and-error treatment. Identifying the underlying genetic cause is crucial not only for prognosis and family planning but also for implementing precision medicine, where specific treatments are tailored to the functional consequences of a mutation.

Methods

Researchers conducted a prospective study of 172 pediatric patients at Qilu Hospital, China. The diagnostic workflow involved:

  1. Targeted NGS: A custom panel capturing 153 known epilepsy-associated genes was sequenced on the Illumina HiSeq X Ten platform.
  2. Bioinformatic Filtering: Variants were filtered against global databases (1000 Genomes, ExAC, HGMD) to exclude common polymorphisms.
  3. Pathogenicity Assessment: Variants were classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines.
  4. Validation: All P/LP variants were confirmed via Sanger sequencing, and parental testing was performed to determine inheritance (de novo vs. inherited).

Key Results

The study achieved an overall diagnostic yield of 23.3% (40/172 patients). The genetic findings were characterized by a high proportion of spontaneous mutations and previously undocumented variants.

The "De Novo" and "Novel" Landscape

Of the 43 P/LP variants identified, 74.4% (32/43) were de novo, meaning they were not inherited from either parent. Furthermore, 60.5% (26/43) were novel, expanding the known mutational spectrum of pediatric epilepsy.

Age of Onset as a Predictor

The timing of the first seizure was a strong predictor of genetic findings. Patients with an onset age ≤ 12 months had a significantly higher yield of deleterious variants compared to those with later onset ($P = 0.006$).

Syndrome-Specific Distribution

The distribution of identified variants varied significantly across clinical phenotypes. Dravet Syndrome (DS) showed the highest concentration of P/LP variants, primarily in the SCN1A gene.

Distribution of total cases and pathogenic/likely pathogenic (P/LP) variants across different epilepsy syndromes.

As shown in the figure above, while syndromes like Dravet Syndrome (DS) and Unclassified Early-onset Epileptic Encephalopathy (UEE) had relatively high diagnostic yields, other categories like Unclassified Epilepsy (UE) had a large number of cases with fewer identified P/LP variants, suggesting further genetic complexity or the involvement of genes not included in the 153-gene panel.

Clinical Significance

Identifying specific genetic drivers had immediate clinical implications:

  • Precision Therapy: In Dravet Syndrome, the identification of SCN1A mutations allows clinicians to avoid sodium channel blockers (e.g., carbamazepine), which can worsen seizures in these patients.
  • Targeted Interventions: Findings in TSC1/TSC2 (Tuberous Sclerosis Complex) or SLC2A1 (GLUT1 deficiency) can lead to the use of mTOR inhibitors or the ketogenic diet, respectively.
  • Genetic Counseling: The high rate of de novo mutations provides reassurance to parents regarding a low recurrence risk for future children.

Discussion and Future Directions

While targeted NGS is cost-effective, the 76.7% of patients without a diagnosis highlight the limitations of a pre-defined gene panel. Future research should leverage whole-exome or whole-genome sequencing to uncover novel epilepsy genes and non-coding variants. Additionally, functional studies (such as electrophysiological assays) are necessary to confirm the exact impact of novel variants on neuronal excitability, paving the way for more refined therapeutic strategies.

Conclusion

This study underscores the genetic diversity of pediatric refractory epilepsy and the critical role of early NGS-based testing. By identifying a high frequency of de novo and novel mutations, particularly in ion channel genes, this work provides a foundation for personalized management and improved outcomes in one of neurology's most challenging patient populations.

Summary updated

Abstract

Pediatric refractory epilepsy is a broad phenotypic spectrum with great genetic heterogeneity. Next-generation sequencing (NGS) combined with Sanger sequencing could help to understand the genetic diversity and underlying disease mechanisms in pediatric epilepsy. Here, we report sequencing results from a cohort of 172 refractory epilepsy patients aged 0-14 years. The pathogenicity of identified variants was evaluated in accordance with the American College of Medical Genetics and Genomics (ACMG) criteria. We identified 43 pathogenic or likely pathogenic variants in 40 patients (23.3%). Among these variants, 74.4% mutations (32/43) were de novo and 60.5% mutations (26/43) were novel. Patients with onset age of seizures ≤12 months had higher yields of deleterious variants compared to those with onset age of seizures > 12 months (P = 0.006). Variants in ion channel genes accounted for the greatest functional gene category (55.8%), with SCN1A coming first (16/43). 81.25% (13/16) of SCN1A mutations were de novo and 68.8% (11/16) were novel in Dravet syndrome. Pathogenic or likely pathogenic variants were found in the KCNQ2, STXBP1, SCN2A genes in Ohtahara syndrome. Novel deleterious variants were also found in West syndrome, Doose syndrome and glucose transporter type 1 deficiency syndrome patients. One de novo MECP2 mutation were found in a Rett syndrome patient. TSC1/TSC2 variants were found in 60% patients with tuberous sclerosis complex patients. Other novel mutations detected in unclassified epilepsy patients involve the SCN8A, CACNA1A, GABRB3, GABRA1, IQSEC2, TSC1, VRK2, ATP1A2, PCDH19, SLC9A6 and CHD2 genes. Our study provides novel insights into the genetic origins of pediatric epilepsy and represents a starting-point for further investigations into the molecular pathophysiology of pediatric epilepsy that could eventually lead to better treatments.
BibTeX
@inproceedings{liu2018novel,
  author = {Jing Liu and Lili Tong and Shuangshuang Song and Yue Niu and Jun Li and Xiu Zhen Wu and Jie Zhang and Clement C. Zai and Fang Luo and Jian Wu and Haiyin Li and Albert H.C. Wong and Ruopeng Sun and Fang Liu and Baomin Li},
  title = {{Novel and de novo mutations in pediatric refractory epilepsy}},
  booktitle = {Molecular},
  year = {2018},
  doi = {10.1186/s13041-018-0392-5},
}
Figure